What Analysts Are Saying About Stryker Stock - Stryker (NYSE:SYK)

Throughout the last three months, 7 analysts have evaluated Stryker (NYSE:SYK), offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

	Bullish	Indifferent
Total Ratings	3	4
Last 30D	0	1
1M Ago	0	1
2M Ago	1	2
3M Ago	2	0

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $322.43, along with a high estimate of $345.00 and a low estimate of $297.00. Surpassing the previous average price target of $300.20, the current average has increased by 7.41%.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light on the perception of Stryker by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Richard Newitter	Truist Securities	Raises	Hold	$320.00	$300.00
Drew Ranieri	Morgan Stanley	Raises	Equal-Weight	$320.00	$300.00
Jason Wittes	Roth MKM	Maintains	Buy	$345.00	-
Danielle Antalffy	UBS	Raises	Neutral	$297.00	$289.00
Richard Newitter	Truist Securities	Raises	Hold	$300.00	$270.00
Jason Wittes	Roth MKM	Announces	Buy	$345.00	-
Joanne Wuensch	Citigroup	Lowers	Buy	$330.00	$342.00

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Stryker compared to the broader market.
Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Stryker's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Stryker's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Stryker analyst ratings.

Unveiling the Story Behind Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.

Unraveling the Financial Story of Stryker

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Stryker displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 9.6%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Stryker's net margin excels beyond industry benchmarks, reaching 14.1%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Stryker's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.92%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Stryker's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.83%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Stryker's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.71.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

SYKStryker Corp

$306.57-0.06%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.